Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.005
+0.185 (10.16%)
May 12, 2025, 3:35 PM - Market open
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Compass Therapeutics stock have an average target of 13.13, with a low estimate of 5.00 and a high estimate of 32. The average target predicts an increase of 554.86% from the current stock price of 2.01.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Compass Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +398.75% | May 9, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,496.01% | Apr 28, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +1,097.01% | Apr 21, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $32 | Strong Buy | Maintains | $32 | +1,496.01% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
1.26M
from 850.00K
Increased by 47.65%
Revenue Next Year
34.17M
from 1.26M
Increased by 2,622.79%
EPS This Year
-0.47
from -0.36
EPS Next Year
-0.53
from -0.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.9M | 81.7M | 240.3M | ||
| Avg | 1.3M | 34.2M | 134.2M | ||
| Low | n/a | 6.3M | 45.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,419.4% | 6,406.7% | 603.1% | ||
| Avg | 47.6% | 2,622.8% | 292.6% | ||
| Low | - | 405.4% | 34.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.20 | -0.25 | 0.09 | ||
| Avg | -0.47 | -0.53 | -0.25 | ||
| Low | -0.65 | -0.80 | -0.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.